Biology subjects

Lopes, E. F.

Publications and source records attributed to Lopes, E. F..

4 recordsLinked to original sources

bioRxiv2026

Kappa opioid receptors regulate cocaine effects on nucleus accumbens dopamine through phosphorylation of dopamine transporter at the threonine 53 site

Chronic cocaine exposure leads to tolerance of the dopamine transporter (DAT) to cocaine and heightened kappa opioid receptor (KOR)-induced inhibition of dopamine (DA) release in the nucleus accumbens (NAc). KORs on presynaptic DA terminals inhibit DA release and modulate DAT function, but whether KOR signaling causes DAT tolerance is unknown. We demonstrate that rats self-administering cocaine escalate their intake, and the KOR antagonist norbinaltorphimine (nBNI) blunts this escalation. We employed fast-scan cyclic voltammetry (FSCV) in acute brain slices containing the NAc core from these rats and found that the cocaine exposure paradigm resulted in tolerance of the DAT to cocaine, an effect absent in animals pre-treated with nBNI. In drug-naive mice, either superfusion of the KOR agonist U50,488 or a single in vivo injection of U69,593 inhibited DA release and reduced cocaine-induced inhibition of DA reuptake, reproducing the tolerance phenotype without any drug history. We replicated this finding in the NAc of rats, and with the uptake inhibitor nomifensine in rhesus macaques, indicating conservation across rodents and non-human primates. As KOR activation results in phosphorylation of the threonine-53 site on the DAT, we tested whether this is required for the KOR-mediated DAT tolerance to cocaine. We show that a mouse line with a phosphorylation-insensitive alanine-53 mutation of the DAT has enhanced DA release and uptake. Remarkably, KOR agonism no longer mediated DAT tolerance to cocaine in these mice, demonstrating the dependence of this effect on the threonine-53 site and highlighting a KOR-driven mechanism underlying cocaine tolerance at the DAT.

neuroscience↗

bioRxiv2025

Kappa opioid receptors delay sucrose self-administration by modulating dopamine ramps before operant responding

Chronic consumption of drugs of abuse increases sensitivity of the dynorphin/kappa opioid receptor (KOR) stress system, which reduces striatal dopamine signaling and promotes drug taking. However, there is mixed evidence on how KOR-modulation of dopamine affects operant behavior in the absence of addiction. To address this gap, we injected dLight1.2 in the nucleus accumbens of male and female C57BL/6J mice and trained them to self-administer sucrose. Mice were injected with the KOR agonist U50,488H, with or without the KOR antagonist aticaprant, prior to each session. U50,488H did not affect dopamine responses during the lever press and did not alter total presses or consumption. The primary effects of KOR activation were to delay initiation of lever pressing, and to diminish the rapid ramp-up in dopamine seen before lever presses. The first lever press of each session was preceded by the largest dopamine ramp; however, ramp size did not correlate with latency under any condition. We further tested whether KOR-modulation of dopamine ramps affects behavior throughout the session. We found that the total amount of dopamine activity 10 seconds before the lever press predicted when the next lever press would occur, specifically after U50,488H injection. When the phasic peaks were subtracted from this to quantify a slower dopamine ramp, time to the next lever press could be predicted and this effect was strongest after U50,488H injection. As U50,488H reduces basal dopamine signaling, we propose that dopamine ramps prior to behavior have a larger signal-to-noise ratio during KOR activation. This relatively greater increase in dopamine from baseline could increase the salience of the decision to perform reward-associated actions, which may play a role in habitual behaviors like drug taking.

neuroscience↗

bioRxiv2025

Gabapentinoids promote striatal dopamine release and rescue multiple deficits of a mouse model of early Parkinson's

Neuronal entry and handling of intracellular calcium have long-been hypothesised to burden vulnerable dopamine neurons in Parkinsons disease. However, no treatments for Parkinsons target calcium biology. Gabapentinoid drugs bind to 2{delta} subunits of voltage-gated calcium channels (VGCCs) and are licensed for neurological disorders including dopamine-dysregulated restless leg syndrome, suggesting their potential utility to modify both calcium biology and dopamine signalling. We therefore tested whether gabapentinoids modulate dopamine signalling, underlying VGCC-dependence, and potential for treating Parkinsons. In mouse striatum, we reveal that gabapentinoids ex vivo promote dopamine release, via sex-specific dependence on 2{delta}1/2 subunits and alterations to the calcium- and VGCC-subtype-dependence of dopamine release or its tonic inhibition by striatal GABA. In vivo administration of gabapentinoids to a mouse model of early Parkinsons rescued deficits in dopamine release, dysregulation of GABAergic inhibition and dopamine content, and abolished parkinsonian deficits in movement transitions. Thus, gabapentinoids urgently deserve attention for repurposing for Parkinsons disease. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=184 SRC="FIGDIR/small/675586v1_ufig1.gif" ALT="Figure 1"> View larger version (51K): org.highwire.dtl.DTLVardef@16cd7e1org.highwire.dtl.DTLVardef@d104e5org.highwire.dtl.DTLVardef@98683eorg.highwire.dtl.DTLVardef@1e3e3ae_HPS_FORMAT_FIGEXP M_FIG C_FIG

neuroscience↗

bioRxiv2019

Astrocytic striatal GABA transporter activity governs dopamine release and shows maladaptive downregulation in early parkinsonism

Striatal dopamine (DA) is critical for action and learning. Recent data show DA release is under tonic inhibition by striatal GABA. Ambient striatal GABA tone on striatal projection neurons can be governed by plasma membrane GABA uptake transporters (GATs) on astrocytes. However, whether striatal GATs and astrocytes determine DA output are unknown. We reveal that DA release in mouse dorsolateral striatum, but not nucleus accumbens core, is governed by GAT-1 and GAT-3. These GATs are partly localized to astrocytes, and are enriched in dorsolateral striatum compared to accumbens core. In a mouse model of early parkinsonism, GATs were downregulated and tonic GABAergic inhibition of DA release augmented, with corresponding attenuation of GABA co-release from dopaminergic axons. These data define previously unappreciated and important roles for GATs and astrocytes in determining DA release in striatum, and reveal a maladaptive plasticity in early parkinsonism that impairs DA output in vulnerable striatal regions. HighlightsO_LIGABA transporters set the level of GABA inhibition of DA output in dorsal striatum C_LIO_LIAstrocytes facilitate DA release levels by limiting tonic GABA inhibition C_LIO_LITonic inhibition of DA release is augmented in a mouse model of early parkinsonism C_LIO_LIDA and GABA co-release are reduced in a mouse model of early parkinsonism C_LI

neuroscience↗